China's National Drug Administration approves PARP inhibitor Lynparza for treatment of patients with advanced ovarian cancer
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, AstraZeneca and Mersadong jointly announced that China's NationalMedicines(http://Regulatory Authority has officially approved its PARP inhibitor Lynparza (Olapari) for the first-line maintenance treatment of patients with advanced ovarian cancer with BRCA mutationOlapari became the first PA p., oraparli, to be approved for first-line maintenance therapy for ovarian cancer, thanks to China's strong support forMedicines(http://innovation and accelerated clinically urgent(http://approvalThe approval is based on positive results from the key Phase III ClinicalTrial(http://SOLO-1 studyThe results showed that, as a first-line maintenance therapy, Olapari had a 70 percent lower risk of progression or death in patients with advanced ovarian cancer who had complete or partial lynosies after receiving platinum-containing chemotherapyAfter a median 41-month follow-up, the Olapali group did not reach the median value of progressionless survival (PFS), compared with 13.8 months in the placebo groupIn the Olapari group, 60 percent of patients had no progress over three years, compared with 27 percent in the placebo group
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
